Sleep, mood disorders and antidepressants: the melatonergic antidepressant agomelatine offers a new strategy for treatment

Autores
Srinivasan, Venkatramanujam; Brzezinski, Amnon; Spence Warren, D.; Pandi Perumal, Seithikurippu R.; Hardeland, Rüdiger; Brown, Gregory M.; Cardinali, Daniel Pedro
Año de publicación
2010
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Insomnia often precedes the appearance of mood changes. While the presence of disturbed sleep prior to the onset of depressed mood is useful prognostically, the ultimate co-occurrence of these symptoms can pose a considerable challenge for pharmaceutical therapy. Most currently used antidepressants (tricyclics, monoamine oxidase inhibitors, serotonin-norepinephrine reuptake inhibitors, serotonin receptor-2 antagonist/serotonin reuptake inhibitors, selective serotonin reuptake inhibitors) are effective antidepressants but they have the disadvantage that often aggravate sleep disturbances. An ideal antidepressant should address both problems: such an antidepressant should exert a rapid onset of action both on depressive symptomatology as well on sleep problems. The recently introduced novel antidepressant agomelatine has melatonergic agonist and 5-HT2C antagonistic properties, and has been found effective in improving both depressive mood and sleep disturbances. Its mechanism of action differs from the currently used antidepressants. It thus represents a possible first line drug for treatment of mood disorders such as major depressive disorder, bipolar disorder and seasonal affective disorder. This review summarises what is known about the clinical efficacy and mechanism of action of agomelatine and compares these findings with those of currently available antidepressants.
Fil: Srinivasan, Venkatramanujam. No especifíca;
Fil: Brzezinski, Amnon. No especifíca;
Fil: Spence Warren, D.. No especifíca;
Fil: Pandi Perumal, Seithikurippu R.. No especifíca;
Fil: Hardeland, Rüdiger. No especifíca;
Fil: Brown, Gregory M.. No especifíca;
Fil: Cardinali, Daniel Pedro. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Materia
INSOMNIA
SLEEP
MOOD DISORDERS
ANTIDEPRESSANTS
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/190921

id CONICETDig_b63a35b5a179d5f88e5e56b3ba22a89a
oai_identifier_str oai:ri.conicet.gov.ar:11336/190921
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Sleep, mood disorders and antidepressants: the melatonergic antidepressant agomelatine offers a new strategy for treatmentSrinivasan, VenkatramanujamBrzezinski, AmnonSpence Warren, D.Pandi Perumal, Seithikurippu R.Hardeland, RüdigerBrown, Gregory M.Cardinali, Daniel PedroINSOMNIASLEEPMOOD DISORDERSANTIDEPRESSANTShttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3Insomnia often precedes the appearance of mood changes. While the presence of disturbed sleep prior to the onset of depressed mood is useful prognostically, the ultimate co-occurrence of these symptoms can pose a considerable challenge for pharmaceutical therapy. Most currently used antidepressants (tricyclics, monoamine oxidase inhibitors, serotonin-norepinephrine reuptake inhibitors, serotonin receptor-2 antagonist/serotonin reuptake inhibitors, selective serotonin reuptake inhibitors) are effective antidepressants but they have the disadvantage that often aggravate sleep disturbances. An ideal antidepressant should address both problems: such an antidepressant should exert a rapid onset of action both on depressive symptomatology as well on sleep problems. The recently introduced novel antidepressant agomelatine has melatonergic agonist and 5-HT2C antagonistic properties, and has been found effective in improving both depressive mood and sleep disturbances. Its mechanism of action differs from the currently used antidepressants. It thus represents a possible first line drug for treatment of mood disorders such as major depressive disorder, bipolar disorder and seasonal affective disorder. This review summarises what is known about the clinical efficacy and mechanism of action of agomelatine and compares these findings with those of currently available antidepressants.Fil: Srinivasan, Venkatramanujam. No especifíca;Fil: Brzezinski, Amnon. No especifíca;Fil: Spence Warren, D.. No especifíca;Fil: Pandi Perumal, Seithikurippu R.. No especifíca;Fil: Hardeland, Rüdiger. No especifíca;Fil: Brown, Gregory M.. No especifíca;Fil: Cardinali, Daniel Pedro. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFoundation for Psychiatric Research in Finland2010-09info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/190921Srinivasan, Venkatramanujam; Brzezinski, Amnon; Spence Warren, D. ; Pandi Perumal, Seithikurippu R.; Hardeland, Rüdiger; et al.; Sleep, mood disorders and antidepressants: the melatonergic antidepressant agomelatine offers a new strategy for treatment; Foundation for Psychiatric Research in Finland; Psychiatria Fennica; 41; 9-2010; 168-1870079-7227CONICET DigitalCONICETenginfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-10T13:25:14Zoai:ri.conicet.gov.ar:11336/190921instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-10 13:25:15.101CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Sleep, mood disorders and antidepressants: the melatonergic antidepressant agomelatine offers a new strategy for treatment
title Sleep, mood disorders and antidepressants: the melatonergic antidepressant agomelatine offers a new strategy for treatment
spellingShingle Sleep, mood disorders and antidepressants: the melatonergic antidepressant agomelatine offers a new strategy for treatment
Srinivasan, Venkatramanujam
INSOMNIA
SLEEP
MOOD DISORDERS
ANTIDEPRESSANTS
title_short Sleep, mood disorders and antidepressants: the melatonergic antidepressant agomelatine offers a new strategy for treatment
title_full Sleep, mood disorders and antidepressants: the melatonergic antidepressant agomelatine offers a new strategy for treatment
title_fullStr Sleep, mood disorders and antidepressants: the melatonergic antidepressant agomelatine offers a new strategy for treatment
title_full_unstemmed Sleep, mood disorders and antidepressants: the melatonergic antidepressant agomelatine offers a new strategy for treatment
title_sort Sleep, mood disorders and antidepressants: the melatonergic antidepressant agomelatine offers a new strategy for treatment
dc.creator.none.fl_str_mv Srinivasan, Venkatramanujam
Brzezinski, Amnon
Spence Warren, D.
Pandi Perumal, Seithikurippu R.
Hardeland, Rüdiger
Brown, Gregory M.
Cardinali, Daniel Pedro
author Srinivasan, Venkatramanujam
author_facet Srinivasan, Venkatramanujam
Brzezinski, Amnon
Spence Warren, D.
Pandi Perumal, Seithikurippu R.
Hardeland, Rüdiger
Brown, Gregory M.
Cardinali, Daniel Pedro
author_role author
author2 Brzezinski, Amnon
Spence Warren, D.
Pandi Perumal, Seithikurippu R.
Hardeland, Rüdiger
Brown, Gregory M.
Cardinali, Daniel Pedro
author2_role author
author
author
author
author
author
dc.subject.none.fl_str_mv INSOMNIA
SLEEP
MOOD DISORDERS
ANTIDEPRESSANTS
topic INSOMNIA
SLEEP
MOOD DISORDERS
ANTIDEPRESSANTS
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Insomnia often precedes the appearance of mood changes. While the presence of disturbed sleep prior to the onset of depressed mood is useful prognostically, the ultimate co-occurrence of these symptoms can pose a considerable challenge for pharmaceutical therapy. Most currently used antidepressants (tricyclics, monoamine oxidase inhibitors, serotonin-norepinephrine reuptake inhibitors, serotonin receptor-2 antagonist/serotonin reuptake inhibitors, selective serotonin reuptake inhibitors) are effective antidepressants but they have the disadvantage that often aggravate sleep disturbances. An ideal antidepressant should address both problems: such an antidepressant should exert a rapid onset of action both on depressive symptomatology as well on sleep problems. The recently introduced novel antidepressant agomelatine has melatonergic agonist and 5-HT2C antagonistic properties, and has been found effective in improving both depressive mood and sleep disturbances. Its mechanism of action differs from the currently used antidepressants. It thus represents a possible first line drug for treatment of mood disorders such as major depressive disorder, bipolar disorder and seasonal affective disorder. This review summarises what is known about the clinical efficacy and mechanism of action of agomelatine and compares these findings with those of currently available antidepressants.
Fil: Srinivasan, Venkatramanujam. No especifíca;
Fil: Brzezinski, Amnon. No especifíca;
Fil: Spence Warren, D.. No especifíca;
Fil: Pandi Perumal, Seithikurippu R.. No especifíca;
Fil: Hardeland, Rüdiger. No especifíca;
Fil: Brown, Gregory M.. No especifíca;
Fil: Cardinali, Daniel Pedro. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
description Insomnia often precedes the appearance of mood changes. While the presence of disturbed sleep prior to the onset of depressed mood is useful prognostically, the ultimate co-occurrence of these symptoms can pose a considerable challenge for pharmaceutical therapy. Most currently used antidepressants (tricyclics, monoamine oxidase inhibitors, serotonin-norepinephrine reuptake inhibitors, serotonin receptor-2 antagonist/serotonin reuptake inhibitors, selective serotonin reuptake inhibitors) are effective antidepressants but they have the disadvantage that often aggravate sleep disturbances. An ideal antidepressant should address both problems: such an antidepressant should exert a rapid onset of action both on depressive symptomatology as well on sleep problems. The recently introduced novel antidepressant agomelatine has melatonergic agonist and 5-HT2C antagonistic properties, and has been found effective in improving both depressive mood and sleep disturbances. Its mechanism of action differs from the currently used antidepressants. It thus represents a possible first line drug for treatment of mood disorders such as major depressive disorder, bipolar disorder and seasonal affective disorder. This review summarises what is known about the clinical efficacy and mechanism of action of agomelatine and compares these findings with those of currently available antidepressants.
publishDate 2010
dc.date.none.fl_str_mv 2010-09
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/190921
Srinivasan, Venkatramanujam; Brzezinski, Amnon; Spence Warren, D. ; Pandi Perumal, Seithikurippu R.; Hardeland, Rüdiger; et al.; Sleep, mood disorders and antidepressants: the melatonergic antidepressant agomelatine offers a new strategy for treatment; Foundation for Psychiatric Research in Finland; Psychiatria Fennica; 41; 9-2010; 168-187
0079-7227
CONICET Digital
CONICET
url http://hdl.handle.net/11336/190921
identifier_str_mv Srinivasan, Venkatramanujam; Brzezinski, Amnon; Spence Warren, D. ; Pandi Perumal, Seithikurippu R.; Hardeland, Rüdiger; et al.; Sleep, mood disorders and antidepressants: the melatonergic antidepressant agomelatine offers a new strategy for treatment; Foundation for Psychiatric Research in Finland; Psychiatria Fennica; 41; 9-2010; 168-187
0079-7227
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Foundation for Psychiatric Research in Finland
publisher.none.fl_str_mv Foundation for Psychiatric Research in Finland
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842981400374935552
score 12.48226